News

AstraZeneca Relies on 3D InSight™ Human Islet Microtissues in Pancreatic Beta-cell Study InSphero human islet model helps reveal the effects of gene silencing on pancreatic

Government research project to predict hepatic clearance of drugs in humans using Akura™ Flow system results in development partnerships with top pharma companies.

Comprehensive, customizable platforms for preclinical drug safety and efficacy testing, coupled with emerging organ-on-a-chip technology, garner investor support

InSphero extends 3D InSight™ Diabetes Discovery Platform to include ALPCO STELLUX® Chemiluminescent ELISA technology for assessment of pancreatic β-cell function.

Global leader in 3D cell culture technology to deliver standardized 3D models in advanced microfluidic format ideal for organ on a chip applications.

Nanosafety experts from more than 30 institutions convene in Swansea, Wales, for PATROLS project kick off meeting.

InSphero demonstrates commitment to customer satisfaction, superior quality, and continuous improvement by adhering to new ISO 9001:2015 standards.

Charles River to license PDX lines to InSphero for development of 3D InSight™ PDX Microtissues, expansion of in vitro oncology services.

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC. The new 3D InSight™ Human Liver Fibrosis Model represents

ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening ETH Zurich researchers present a single-islet study using a novel microfluidic

Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury An Archives of Toxicology publication reveals

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS) A joint study will accelerate the development of physiologically relevant 3D models for